ETFOptimize | High-performance ETF-based Investment Strategies

Quantitative strategies, Wall Street-caliber research, and insightful market analysis since 1998.


ETFOptimize | HOME
Close Window

McKesson (MCK) Stock Is Up, What You Need To Know

MCK Cover Image

What Happened?

Shares of healthcare distributor and services company McKesson (NYSE: MCK) jumped 2.6% in the morning session after the positive momentum continued as it raised its profit forecast for fiscal 2026 and boosted its long-term growth targets during its 2025 Investor Day. 

The company increased its fiscal 2026 adjusted earnings per share guidance to a new range of $38.05 to $38.55, up from the previous forecast of $37.10 to $37.90. This updated outlook topped consensus estimates. McKesson also lifted its long-term adjusted earnings growth target to a range of 13% to 16%, an increase from the prior 12% to 14%. The positive revision was linked to the company's plans to focus on high-margin areas, such as cancer medicines. 

Following the announcement, Morgan Stanley raised its price target on the shares to $857 from $810, citing the strong guidance.

After the initial pop the shares cooled down to $759.01, up 2.4% from previous close.

Is now the time to buy McKesson? Access our full analysis report here, it’s free.

What Is The Market Telling Us

McKesson’s shares are not very volatile and have only had 4 moves greater than 5% over the last year. In that context, today’s move indicates the market considers this news meaningful, although it might not be something that would fundamentally change its perception of the business.

The previous big move we wrote about was 1 day ago when the stock gained 6.6% on the news that the company raised its profit forecast for fiscal 2026 and boosted its long-term growth targets during its 2025 Investor Day. 

During the event, McKesson's leaders unveiled a higher forecast for Fiscal 2026 adjusted earnings per share, setting a new range of $38.05 to $38.55. This new target topped the prior range and also surpassed market estimates. The company also showed more confidence in its future, increasing its long-term adjusted earnings growth goal to a range of 13% to 16%, up from 12% to 14%. 

Management pointed to the strength of its platforms in high-value areas like oncology and biopharma solutions as key drivers for this improved outlook. The move suggested a clear strategy to focus on more profitable parts of its business.

McKesson is up 34.1% since the beginning of the year, and at $759.01 per share, has set a new 52-week high. Investors who bought $1,000 worth of McKesson’s shares 5 years ago would now be looking at an investment worth $5,179.

Do you want to know what moves the business you care about? Add them to your StockStory watchlist and every time a stock significantly moves, we provide you with a timely explanation straight to your inbox. It’s free and will only take you a second.

Recent Quotes

View More
Symbol Price Change (%)
AMZN  230.30
+1.05 (0.46%)
AAPL  269.70
+0.70 (0.26%)
AMD  264.33
+6.32 (2.45%)
BAC  52.58
-0.29 (-0.55%)
GOOG  275.17
+6.74 (2.51%)
META  751.67
+0.23 (0.03%)
MSFT  541.55
-0.52 (-0.10%)
NVDA  207.04
+6.01 (2.99%)
ORCL  275.30
-5.53 (-1.97%)
TSLA  461.51
+0.96 (0.21%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.


 

IntelligentValue Home
Close Window

DISCLAIMER

All content herein is issued solely for informational purposes and is not to be construed as an offer to sell or the solicitation of an offer to buy, nor should it be interpreted as a recommendation to buy, hold or sell (short or otherwise) any security.  All opinions, analyses, and information included herein are based on sources believed to be reliable, but no representation or warranty of any kind, expressed or implied, is made including but not limited to any representation or warranty concerning accuracy, completeness, correctness, timeliness or appropriateness. We undertake no obligation to update such opinions, analysis or information. You should independently verify all information contained on this website. Some information is based on analysis of past performance or hypothetical performance results, which have inherent limitations. We make no representation that any particular equity or strategy will or is likely to achieve profits or losses similar to those shown. Shareholders, employees, writers, contractors, and affiliates associated with ETFOptimize.com may have ownership positions in the securities that are mentioned. If you are not sure if ETFs, algorithmic investing, or a particular investment is right for you, you are urged to consult with a Registered Investment Advisor (RIA). Neither this website nor anyone associated with producing its content are Registered Investment Advisors, and no attempt is made herein to substitute for personalized, professional investment advice. Neither ETFOptimize.com, Global Alpha Investments, Inc., nor its employees, service providers, associates, or affiliates are responsible for any investment losses you may incur as a result of using the information provided herein. Remember that past investment returns may not be indicative of future returns.

Copyright © 1998-2017 ETFOptimize.com, a publication of Optimized Investments, Inc. All rights reserved.